Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/333628

Lähdeviite

Bousquet , J , Le Moing , V , Blain , H , Czarlewski , W , Zuberbier , T , Torre , R D L , Lozano , N P , Reynes , J , Bedbrook , A , Cristol , J-P , Cruz , A A , Fiocchi , A , Haahtela , T , Iaccarino , G , Klimek , L , Kuna , P , Melén , E , Mullol , J , Samolinski , B , Valiulis , A & Anto , J M 2021 , ' Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases ' , World Allergy Organization journal , vol. 14 , no. 1 , 100498 . https://doi.org/10.1016/j.waojou.2020.100498

Julkaisun nimi: Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases
Tekijä: Bousquet, Jean; Le Moing, Vincent; Blain, Hubert; Czarlewski, Wienczyslawa; Zuberbier, Torsten; Torre, Raphael de la; Lozano, Nieves Pizarro; Reynes, Jacques; Bedbrook, Anna; Cristol, Jean-Paul; Cruz, Alvaro A.; Fiocchi, Alessandro; Haahtela, Tari; Iaccarino, Guido; Klimek, Ludger; Kuna, Piotr; Melén, Erik; Mullol, Joaquim; Samolinski, Boleslaw; Valiulis, Arunas; Anto, Josep M.
Tekijän organisaatio: Department of Dermatology, Allergology and Venereology
HUS Inflammation Center
Päiväys: 2021-01
Kieli: eng
Sivumäärä: 16
Kuuluu julkaisusarjaan: World Allergy Organization journal
ISSN: 1939-4551
DOI-tunniste: https://doi.org/10.1016/j.waojou.2020.100498
URI: http://hdl.handle.net/10138/333628
Tiivistelmä: COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first COVID-19 symptoms. They were found to reduce many of the symptoms rapidly and for a duration of 6-12 h by repeated dosing. When the patient was stable but still suffering from cough and nasal obstruction when not taking the broccoli capsules, a double-blind induced cough challenge confirmed the speed of onset of the capsules (less than 10 min). A second clinical case with lower broccoli doses carried out during the cytokine storm confirmed the clinical benefits already observed. A third clinical case showed similar effects at the onset of symptoms. In the first clinical trial, we used a dose of under 600 mmol per day of glucoraphanin. However, such a high dose may induce pharmacologic effects that require careful examination before the performance of any study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2interacting nutrients are effective in COVID-19. However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety.
Avainsanat: 3121 General medicine, internal medicine and other clinical medicine
COVID-19
Nrf2
broccoli
cough challenge
TRPA1
TRPV1
ACTIVATION
MECHANISM
SULFORAPHANE
STRATEGY
CHEMOPREVENTION
INDUCED CARDIOMYOPATHY
Cough challenge
RHINITIS
Broccoli
NRF2
RICH
COUGH
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
1_s2.0_S1939455120304014_main.pdf 1.418MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot